Search

Your search keyword '"Abramson, Vandana G."' showing total 329 results
Start Over Author "Abramson, Vandana G."
329 results on '"Abramson, Vandana G."'

1. A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Author

Mezzanotte-Sharpe, Jessica, ONeill, Anne, Mayer, Ingrid A., Arteaga, Carlos L., Yang, Ximing J., Wagner, Lynne I., Cella, David, Meropol, Neal J., Alpaugh, R. Katherine, Saphner, Thomas J., Swaney, Robert E., Hoelzer, Karen L., Gradishar, William J., Abramson, Vandana G., Sundaram, P. Kothai, Jilani, Shamim Z., Perez, Edith A., Lin, Nancy U., Jahanzeb, Mohammad, Wolff, Antonio C., Sledge, George W., and Reid, Sonya A.

Published
2024
Full Text
View/download PDF

2. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

Author

Lenz, Lauren, Neff, Chris, Solimeno, Cara, Cogan, Elizabeth S., Abramson, Vandana G., Boughey, Judy C., Falkson, Carla, Goetz, Matthew P., Ford, James M., Gradishar, William J., Jankowitz, Rachel C., Kaklamani, Virginia G., Marcom, P. Kelly, Richardson, Andrea L., Storniolo, Anna Maria, Tung, Nadine M., Vinayak, Shaveta, Hodgson, Darren R., Lai, Zhongwu, Dearden, Simon, Hennessy, Bryan T., Mayer, Erica L., Mills, Gordon B., Slavin, Thomas P., Gutin, Alexander, Connolly, Roisin M., Telli, Melinda L., Stearns, Vered, Lanchbury, Jerry S., and Timms, Kirsten M.

Published
2023
Full Text
View/download PDF

3. Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.

Author

Axelrod, Margaret L, Nixon, Mellissa J, Gonzalez-Ericsson, Paula I, Bergman, Riley E, Pilkinton, Mark A, McDonnell, Wyatt J, Sanchez, Violeta, Opalenik, Susan R, Loi, Sherene, Zhou, Jing, Mackay, Sean, Rexer, Brent N, Abramson, Vandana G, Jansen, Valerie M, Mallal, Simon, Donaldson, Joshua, Tolaney, Sara M, Krop, Ian E, Garrido-Castro, Ana C, Marotti, Jonathan D, Shee, Kevin, Miller, Todd W, Sanders, Melinda E, Mayer, Ingrid A, Salgado, Roberto, and Balko, Justin M

Subjects
CD8-Positive T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Humans, Neoplasm Recurrence, Local, Paclitaxel, Albumins, Neoplasm Proteins, Antineoplastic Combined Chemotherapy Protocols, Prognosis, Treatment Outcome, Neoadjuvant Therapy, Gene Expression Regulation, Neoplastic, Adult, Aged, Middle Aged, Female, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Triple Negative Breast Neoplasms, B7-H1 Antigen, Progression-Free Survival, Clinical Research, Genetics, Breast Cancer, Cancer, 2.1 Biological and endogenous factors, Aetiology, Good Health and Well Being, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe recent approval of anti-programmed death-ligand 1 immunotherapy in combination with nab-paclitaxel for metastatic triple-negative breast cancer (TNBC) highlights the need to understand the role of chemotherapy in modulating the tumor immune microenvironment (TIME).Experimental designWe examined immune-related gene expression patterns before and after neoadjuvant chemotherapy (NAC) in a series of 83 breast tumors, including 44 TNBCs, from patients with residual disease (RD). Changes in gene expression patterns in the TIME were tested for association with recurrence-free (RFS) and overall survival (OS). In addition, we sought to characterize the systemic effects of NAC through single-cell analysis (RNAseq and cytokine secretion) of programmed death-1-high (PD-1HI) CD8+ peripheral T cells and examination of a cytolytic gene signature in whole blood.ResultsIn non-TNBC, no change in expression of any single gene was associated with RFS or OS, while in TNBC upregulation of multiple immune-related genes and gene sets were associated with improved long-term outcome. High cytotoxic T-cell signatures present in the peripheral blood of patients with breast cancer at surgery were associated with persistent disease and recurrence, suggesting active antitumor immunity that may indicate ongoing disease burden.ConclusionsWe have characterized the effects of NAC on the TIME, finding that TNBC is uniquely sensitive to the immunologic effects of NAC, and local increases in immune genes/sets are associated with improved outcomes. However, expression of cytotoxic genes in the peripheral blood, as opposed to the TIME, may be a minimally invasive biomarker of persistent micrometastatic disease ultimately leading to recurrence.

Published
2020

5. Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer (MBC) with a somatic BRCA1/2mutation identified in a cell-free DNA or tumor tissue genotyping assay.

Author

Vidula, Neelima, primary, Damodaran, Senthil, additional, Bhave, Manali A., additional, Blouch, Erica, additional, Ogbenna, Ogadinma, additional, Flaum, Lisa E., additional, Shah, Ami N., additional, Abramson, Vandana G, additional, Cristofanilli, Massimo, additional, Sparano, Joseph A., additional, Ostrer, Harry, additional, Horick, Nora K., additional, Rugo, Hope S., additional, and Bardia, Aditya, additional

Published
2024
Full Text
View/download PDF

6. RNA-Seq based gene expression profiling of baseline and on-treatment breast tumors to predict response to HER2-directed therapy, without chemotherapy (TBCRC026).

Author

Hennessy, Maeve, primary, Fernández, Aranzazu, additional, Huang, Chiung Yu, additional, Cimino-Mathews, Ashley, additional, Denbow, Rita, additional, Abramson, Vandana G, additional, Rimawi, Mothaffar F., additional, Specht, Jennifer M., additional, Storniolo, Anna Maria, additional, Valero, Vicente, additional, Vaklavas, Chris, additional, Winer, Eric P., additional, Krop, Ian E., additional, Wolff, Antonio C., additional, Wahl, Richard L., additional, Thompson, E Aubrey, additional, Stearns, Vered, additional, Perou, Charles, additional, Carey, Lisa A., additional, and Connolly, Roisin M., additional

Published
2024
Full Text
View/download PDF

7. Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030.

Author

Nader Marta, Guilherme, primary, Chu, Xiangying, additional, Mukhopadhyay, Satabhisa, additional, Abramson, Vandana G, additional, Brufsky, Adam, additional, Stringer-Reasor, Erica Michelle, additional, Dent, Susan Faye, additional, Traina, Tiffany A., additional, Carey, Lisa A., additional, Rimawi, Mothaffar F., additional, Specht, Jennifer M., additional, Miller, Kathy, additional, Santa-Maria, Cesar Augusto, additional, Dasgupta, Tathagata, additional, Binboğa Kurt, Busem, additional, Tayob, Nabihah, additional, Krop, Ian E., additional, Tung, Nadine M., additional, Schnitt, Stuart J., additional, and Mayer, Erica L., additional

Published
2024
Full Text
View/download PDF

9. A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Author

Mezzanotte-Sharpe, Jessica, primary, ONeill, Anne, additional, Mayer, Ingrid A., additional, Arteaga, Carlos L., additional, Yang, Ximing J, additional, Wagner, Lynne I., additional, Cella, David, additional, Meropol, Neal J., additional, Alpaugh, R. Katherine, additional, Saphner, Thomas J., additional, Swaney, Robert E., additional, Hoelzer, Karen L, additional, Gradishar, William J., additional, Abramson, Vandana G., additional, Sundaram, P. Kothai, additional, Jilani, Shamim Z., additional, Perez, Edith A., additional, Lin, Nancy U., additional, Jahanzeb, Mohammad, additional, Wolff, Antonio C., additional, Sledge, George W., additional, and Reid, Sonya A., additional

Published
2024
Full Text
View/download PDF

10. FIGURE 6 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer

Author

Wescott, Elizabeth C., primary, Sun, Xiaopeng, primary, Gonzalez-Ericsson, Paula, primary, Hanna, Ann, primary, Taylor, Brandie C., primary, Sanchez, Violeta, primary, Bronzini, Juliana, primary, Opalenik, Susan R., primary, Sanders, Melinda E., primary, Wulfkuhle, Julia, primary, Gallagher, Rosa I., primary, Gomez, Henry, primary, Isaacs, Claudine, primary, Bharti, Vijaya, primary, Wilson, John T., primary, Ballinger, Tarah J., primary, Santa-Maria, Cesar A., primary, Shah, Payal D., primary, Dees, Elizabeth C., primary, Lehmann, Brian D., primary, Abramson, Vandana G., primary, Hirst, Gillian L., primary, Brown Swigart, Lamorna, primary, van ˈt Veer, Laura J., primary, Esserman, Laura J., primary, Petricoin, Emanuel F., primary, Pietenpol, Jennifer A., primary, and Balko, Justin M., primary

Published
2024
Full Text
View/download PDF

11. Figure S2 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer

Author

Wescott, Elizabeth C., primary, Sun, Xiaopeng, primary, Gonzalez-Ericsson, Paula, primary, Hanna, Ann, primary, Taylor, Brandie C., primary, Sanchez, Violeta, primary, Bronzini, Juliana, primary, Opalenik, Susan R., primary, Sanders, Melinda E., primary, Wulfkuhle, Julia, primary, Gallagher, Rosa I., primary, Gomez, Henry, primary, Isaacs, Claudine, primary, Bharti, Vijaya, primary, Wilson, John T., primary, Ballinger, Tarah J., primary, Santa-Maria, Cesar A., primary, Shah, Payal D., primary, Dees, Elizabeth C., primary, Lehmann, Brian D., primary, Abramson, Vandana G., primary, Hirst, Gillian L., primary, Brown Swigart, Lamorna, primary, van ˈt Veer, Laura J., primary, Esserman, Laura J., primary, Petricoin, Emanuel F., primary, Pietenpol, Jennifer A., primary, and Balko, Justin M., primary

Published
2024
Full Text
View/download PDF

12. FIGURE 3 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer

Author

Wescott, Elizabeth C., primary, Sun, Xiaopeng, primary, Gonzalez-Ericsson, Paula, primary, Hanna, Ann, primary, Taylor, Brandie C., primary, Sanchez, Violeta, primary, Bronzini, Juliana, primary, Opalenik, Susan R., primary, Sanders, Melinda E., primary, Wulfkuhle, Julia, primary, Gallagher, Rosa I., primary, Gomez, Henry, primary, Isaacs, Claudine, primary, Bharti, Vijaya, primary, Wilson, John T., primary, Ballinger, Tarah J., primary, Santa-Maria, Cesar A., primary, Shah, Payal D., primary, Dees, Elizabeth C., primary, Lehmann, Brian D., primary, Abramson, Vandana G., primary, Hirst, Gillian L., primary, Brown Swigart, Lamorna, primary, van ˈt Veer, Laura J., primary, Esserman, Laura J., primary, Petricoin, Emanuel F., primary, Pietenpol, Jennifer A., primary, and Balko, Justin M., primary

Published
2024
Full Text
View/download PDF

13. FIGURE 2 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer

Author

Wescott, Elizabeth C., primary, Sun, Xiaopeng, primary, Gonzalez-Ericsson, Paula, primary, Hanna, Ann, primary, Taylor, Brandie C., primary, Sanchez, Violeta, primary, Bronzini, Juliana, primary, Opalenik, Susan R., primary, Sanders, Melinda E., primary, Wulfkuhle, Julia, primary, Gallagher, Rosa I., primary, Gomez, Henry, primary, Isaacs, Claudine, primary, Bharti, Vijaya, primary, Wilson, John T., primary, Ballinger, Tarah J., primary, Santa-Maria, Cesar A., primary, Shah, Payal D., primary, Dees, Elizabeth C., primary, Lehmann, Brian D., primary, Abramson, Vandana G., primary, Hirst, Gillian L., primary, Brown Swigart, Lamorna, primary, van ˈt Veer, Laura J., primary, Esserman, Laura J., primary, Petricoin, Emanuel F., primary, Pietenpol, Jennifer A., primary, and Balko, Justin M., primary

Published
2024
Full Text
View/download PDF

14. Table S4 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer

Author

Wescott, Elizabeth C., primary, Sun, Xiaopeng, primary, Gonzalez-Ericsson, Paula, primary, Hanna, Ann, primary, Taylor, Brandie C., primary, Sanchez, Violeta, primary, Bronzini, Juliana, primary, Opalenik, Susan R., primary, Sanders, Melinda E., primary, Wulfkuhle, Julia, primary, Gallagher, Rosa I., primary, Gomez, Henry, primary, Isaacs, Claudine, primary, Bharti, Vijaya, primary, Wilson, John T., primary, Ballinger, Tarah J., primary, Santa-Maria, Cesar A., primary, Shah, Payal D., primary, Dees, Elizabeth C., primary, Lehmann, Brian D., primary, Abramson, Vandana G., primary, Hirst, Gillian L., primary, Brown Swigart, Lamorna, primary, van ˈt Veer, Laura J., primary, Esserman, Laura J., primary, Petricoin, Emanuel F., primary, Pietenpol, Jennifer A., primary, and Balko, Justin M., primary

Published
2024
Full Text
View/download PDF

15. FIGURE 4 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer

Author

Wescott, Elizabeth C., primary, Sun, Xiaopeng, primary, Gonzalez-Ericsson, Paula, primary, Hanna, Ann, primary, Taylor, Brandie C., primary, Sanchez, Violeta, primary, Bronzini, Juliana, primary, Opalenik, Susan R., primary, Sanders, Melinda E., primary, Wulfkuhle, Julia, primary, Gallagher, Rosa I., primary, Gomez, Henry, primary, Isaacs, Claudine, primary, Bharti, Vijaya, primary, Wilson, John T., primary, Ballinger, Tarah J., primary, Santa-Maria, Cesar A., primary, Shah, Payal D., primary, Dees, Elizabeth C., primary, Lehmann, Brian D., primary, Abramson, Vandana G., primary, Hirst, Gillian L., primary, Brown Swigart, Lamorna, primary, van ˈt Veer, Laura J., primary, Esserman, Laura J., primary, Petricoin, Emanuel F., primary, Pietenpol, Jennifer A., primary, and Balko, Justin M., primary

Published
2024
Full Text
View/download PDF

16. FIGURE 5 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer

Author

Wescott, Elizabeth C., primary, Sun, Xiaopeng, primary, Gonzalez-Ericsson, Paula, primary, Hanna, Ann, primary, Taylor, Brandie C., primary, Sanchez, Violeta, primary, Bronzini, Juliana, primary, Opalenik, Susan R., primary, Sanders, Melinda E., primary, Wulfkuhle, Julia, primary, Gallagher, Rosa I., primary, Gomez, Henry, primary, Isaacs, Claudine, primary, Bharti, Vijaya, primary, Wilson, John T., primary, Ballinger, Tarah J., primary, Santa-Maria, Cesar A., primary, Shah, Payal D., primary, Dees, Elizabeth C., primary, Lehmann, Brian D., primary, Abramson, Vandana G., primary, Hirst, Gillian L., primary, Brown Swigart, Lamorna, primary, van ˈt Veer, Laura J., primary, Esserman, Laura J., primary, Petricoin, Emanuel F., primary, Pietenpol, Jennifer A., primary, and Balko, Justin M., primary

Published
2024
Full Text
View/download PDF

17. Data from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer

Author

Wescott, Elizabeth C., primary, Sun, Xiaopeng, primary, Gonzalez-Ericsson, Paula, primary, Hanna, Ann, primary, Taylor, Brandie C., primary, Sanchez, Violeta, primary, Bronzini, Juliana, primary, Opalenik, Susan R., primary, Sanders, Melinda E., primary, Wulfkuhle, Julia, primary, Gallagher, Rosa I., primary, Gomez, Henry, primary, Isaacs, Claudine, primary, Bharti, Vijaya, primary, Wilson, John T., primary, Ballinger, Tarah J., primary, Santa-Maria, Cesar A., primary, Shah, Payal D., primary, Dees, Elizabeth C., primary, Lehmann, Brian D., primary, Abramson, Vandana G., primary, Hirst, Gillian L., primary, Brown Swigart, Lamorna, primary, van ˈt Veer, Laura J., primary, Esserman, Laura J., primary, Petricoin, Emanuel F., primary, Pietenpol, Jennifer A., primary, and Balko, Justin M., primary

Published
2024
Full Text
View/download PDF

18. FIGURE 1 from Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer

Author

Wescott, Elizabeth C., primary, Sun, Xiaopeng, primary, Gonzalez-Ericsson, Paula, primary, Hanna, Ann, primary, Taylor, Brandie C., primary, Sanchez, Violeta, primary, Bronzini, Juliana, primary, Opalenik, Susan R., primary, Sanders, Melinda E., primary, Wulfkuhle, Julia, primary, Gallagher, Rosa I., primary, Gomez, Henry, primary, Isaacs, Claudine, primary, Bharti, Vijaya, primary, Wilson, John T., primary, Ballinger, Tarah J., primary, Santa-Maria, Cesar A., primary, Shah, Payal D., primary, Dees, Elizabeth C., primary, Lehmann, Brian D., primary, Abramson, Vandana G., primary, Hirst, Gillian L., primary, Brown Swigart, Lamorna, primary, van ˈt Veer, Laura J., primary, Esserman, Laura J., primary, Petricoin, Emanuel F., primary, Pietenpol, Jennifer A., primary, and Balko, Justin M., primary

Published
2024
Full Text
View/download PDF

19. TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer

Author

Forero-Torres, Andres, Consortium, on behalf of the Translational Breast Cancer Research, Varley, Katherine E, Abramson, Vandana G, Li, Yufeng, Vaklavas, Christos, Lin, Nancy U, Liu, Minetta C, Rugo, Hope S, Nanda, Rita, Storniolo, Anna M, Traina, Tiffany A, Patil, Sujata, Van Poznak, Catherine H, Nangia, Julie R, Irvin, William J, Krontiras, Helen, De Los Santos, Jennifer F, Haluska, Paul, Grizzle, William, Myers, Richard M, and Wolff, Antonio C

Subjects
Clinical Research, Cancer, Breast Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Biopsy, Female, Humans, Middle Aged, Nanoparticles, Paclitaxel, Receptors, TNF-Related Apoptosis-Inducing Ligand, Retreatment, Treatment Outcome, Triple Negative Breast Neoplasms, Translational Breast Cancer Research Consortium, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeTigatuzumab (TIG), an agonistic anti-DR5 antibody, triggers apoptosis in DR5(+) human tumor cells without crosslinking. TIG has strong in vitro/in vivo activity against basal-like breast cancer cells enhanced by chemotherapy agents. This study evaluates activity of TIG and chemotherapy in patients with metastatic triple-negative breast cancer (TNBC).Experimental designRandomized 2:1 phase II trial of albumin-bound paclitaxel (nab-PAC) ± TIG in patients with TNBC stratified by prior chemotherapy. Patients received nab-PAC weekly × 3 ± TIG every other week, every 28 days. Primary objective was within-arm objective response rate (ORR). Secondary objectives were safety, progression-free survival (PFS), clinical benefit, and TIG immunogenicity. Metastatic research biopsies were required.ResultsAmong 64 patients (60 treated; TIG/nab-PAC n = 39 and nab-PAC n = 21), there were 3 complete remissions (CR), 8 partial remissions (PR; 1 almost CR), 11 stable diseases (SD), and 17 progressive diseases (PD) in the TIG/nab-PAC arm (ORR, 28%), and no CRs, 8 PRs, 4 SDs, and 9 PDs in the nab-PAC arm (ORR, 38%). There was a numerical increase in CRs and several patients had prolonged PFS (1,025+, 781, 672, 460, 334) in the TIG/nab-PAC arm. Grade 3 toxicities were 28% and 29%, respectively, with no grade 4-5. Exploratory analysis suggests an association of ROCK1 gene pathway activation with efficacy in the TIG/nab-PAC arm.ConclusionsORR and PFS were similar in both. Preclinical activity of TIG in basal-like breast cancer and prolonged PFS in few patients in the combination arm support further investigation of anti-DR5 agents. ROCK pathway activation merits further evaluation.

Published
2015

20. Supplementary Figure 5 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer

Author

Taylor, Brandie C., primary, Sun, Xiaopeng, primary, Gonzalez-Ericsson, Paula I., primary, Sanchez, Violeta, primary, Sanders, Melinda E., primary, Wescott, Elizabeth C., primary, Opalenik, Susan R., primary, Hanna, Ann, primary, Chou, Shu-Ting, primary, Van Kaer, Luc, primary, Gomez, Henry, primary, Isaacs, Claudine, primary, Ballinger, Tarah J., primary, Santa-Maria, Cesar A., primary, Shah, Payal D., primary, Dees, Elizabeth C., primary, Lehmann, Brian D., primary, Abramson, Vandana G., primary, Pietenpol, Jennifer A., primary, and Balko, Justin M., primary

Published
2024
Full Text
View/download PDF

21. Supplementary Figure 2 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer

Author

Taylor, Brandie C., primary, Sun, Xiaopeng, primary, Gonzalez-Ericsson, Paula I., primary, Sanchez, Violeta, primary, Sanders, Melinda E., primary, Wescott, Elizabeth C., primary, Opalenik, Susan R., primary, Hanna, Ann, primary, Chou, Shu-Ting, primary, Van Kaer, Luc, primary, Gomez, Henry, primary, Isaacs, Claudine, primary, Ballinger, Tarah J., primary, Santa-Maria, Cesar A., primary, Shah, Payal D., primary, Dees, Elizabeth C., primary, Lehmann, Brian D., primary, Abramson, Vandana G., primary, Pietenpol, Jennifer A., primary, and Balko, Justin M., primary

Published
2024
Full Text
View/download PDF

22. Supplementary Figure 7 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer

Author

Taylor, Brandie C., primary, Sun, Xiaopeng, primary, Gonzalez-Ericsson, Paula I., primary, Sanchez, Violeta, primary, Sanders, Melinda E., primary, Wescott, Elizabeth C., primary, Opalenik, Susan R., primary, Hanna, Ann, primary, Chou, Shu-Ting, primary, Van Kaer, Luc, primary, Gomez, Henry, primary, Isaacs, Claudine, primary, Ballinger, Tarah J., primary, Santa-Maria, Cesar A., primary, Shah, Payal D., primary, Dees, Elizabeth C., primary, Lehmann, Brian D., primary, Abramson, Vandana G., primary, Pietenpol, Jennifer A., primary, and Balko, Justin M., primary

Published
2024
Full Text
View/download PDF

23. Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer

Author

Lehmann, Brian D., primary, Abramson, Vandana G., additional, Dees, E. Claire, additional, Shah, Payal D., additional, Ballinger, Tarah J., additional, Isaacs, Claudine, additional, Santa-Maria, Cesar A., additional, An, Hanbing, additional, Gonzalez-Ericsson, Paula I., additional, Sanders, Melinda E., additional, Newsom, Kimberly C., additional, Abramson, Richard G., additional, Sheng, Quanhu, additional, Hsu, Chih-Yuan, additional, Shyr, Yu, additional, Wolff, Antonio C., additional, and Pietenpol, Jennifer A., additional

Published
2024
Full Text
View/download PDF

24. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer

Author

Abramson, Vandana G., Oliveira, Mafalda, Cervantes, Andrés, Wildiers, Hans, Patel, Manish R., Bauer, Todd M., Bedard, Philippe L., Becerra, Carlos, Richey, Stephen, Wei, Michael C., Reyner, Eric, Bond, John, Cui, Na, Wilson, Timothy R., Moore, Heather M., Saura, Cristina, and Krop, Ian E.

Published
2019
Full Text
View/download PDF

26. NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer

Author

Taylor, Brandie C., primary, Sun, Xiaopeng, additional, Gonzalez-Ericsson, Paula I., additional, Sanchez, Violeta, additional, Sanders, Melinda E., additional, Wescott, Elizabeth C., additional, Opalenik, Susan R., additional, Hanna, Ann, additional, Chou, Shu-Ting, additional, Van Kaer, Luc, additional, Gomez, Henry, additional, Isaacs, Claudine, additional, Ballinger, Tarah J., additional, Santa-Maria, Cesar A., additional, Shah, Payal D., additional, Dees, Elizabeth C., additional, Lehmann, Brian D., additional, Abramson, Vandana G., additional, Pietenpol, Jennifer A., additional, and Balko, Justin M., additional

Published
2023
Full Text
View/download PDF

27. Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial)

Author

Hennessy, Maeve A., primary, Leal, Jeffrey P., additional, Huang, Chiung-Yu, additional, Solnes, Lilja B., additional, Denbow, Rita, additional, Abramson, Vandana G., additional, Carey, Lisa A., additional, Liu, Minetta C., additional, Rimawi, Mothaffar, additional, Specht, Jennifer, additional, Storniolo, Anna Maria, additional, Valero, Vicente, additional, Vaklavas, Christos, additional, Winer, Eric P., additional, Krop, Ian E., additional, Wolff, Antonio C., additional, Cimino-Mathews, Ashley, additional, Wahl, Richard L., additional, Stearns, Vered, additional, and Connolly, Roisin M., additional

Published
2023
Full Text
View/download PDF

28. Feasibility and Tolerability of Adjuvant Capecitabine–Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospective Clinical Trial

Author

Balbach, Meridith L., primary, Sherry, Alexander D., additional, Rexer, Brent N., additional, Abramson, Vandana G., additional, Niermann, Kenneth J., additional, Johnson, Corbin R., additional, Park, Ben Ho, additional, Mayer, Ingrid A., additional, and Chakravarthy, A. Bapsi, additional

Published
2023
Full Text
View/download PDF

30. Data from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

Author

Filho, Otto Metzger, primary, Viale, Giuseppe, primary, Stein, Shayna, primary, Trippa, Lorenzo, primary, Yardley, Denise A., primary, Mayer, Ingrid A., primary, Abramson, Vandana G., primary, Arteaga, Carlos L., primary, Spring, Laura M., primary, Waks, Adrienne G., primary, Wrabel, Eileen, primary, DeMeo, Michelle K., primary, Bardia, Aditya, primary, Dell'Orto, Patrizia, primary, Russo, Leila, primary, King, Tari A., primary, Polyak, Kornelia, primary, Michor, Franziska, primary, Winer, Eric P., primary, and Krop, Ian E., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Fig. S3 from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

Author

Filho, Otto Metzger, primary, Viale, Giuseppe, primary, Stein, Shayna, primary, Trippa, Lorenzo, primary, Yardley, Denise A., primary, Mayer, Ingrid A., primary, Abramson, Vandana G., primary, Arteaga, Carlos L., primary, Spring, Laura M., primary, Waks, Adrienne G., primary, Wrabel, Eileen, primary, DeMeo, Michelle K., primary, Bardia, Aditya, primary, Dell'Orto, Patrizia, primary, Russo, Leila, primary, King, Tari A., primary, Polyak, Kornelia, primary, Michor, Franziska, primary, Winer, Eric P., primary, and Krop, Ian E., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table S2 from Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

Author

Filho, Otto Metzger, primary, Viale, Giuseppe, primary, Stein, Shayna, primary, Trippa, Lorenzo, primary, Yardley, Denise A., primary, Mayer, Ingrid A., primary, Abramson, Vandana G., primary, Arteaga, Carlos L., primary, Spring, Laura M., primary, Waks, Adrienne G., primary, Wrabel, Eileen, primary, DeMeo, Michelle K., primary, Bardia, Aditya, primary, Dell'Orto, Patrizia, primary, Russo, Leila, primary, King, Tari A., primary, Polyak, Kornelia, primary, Michor, Franziska, primary, Winer, Eric P., primary, and Krop, Ian E., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Dataset 1 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

Author

Axelrod, Margaret L., primary, Nixon, Mellissa J., primary, Gonzalez-Ericsson, Paula I., primary, Bergman, Riley E., primary, Pilkinton, Mark A., primary, McDonnell, Wyatt J., primary, Sanchez, Violeta, primary, Opalenik, Susan R., primary, Loi, Sherene, primary, Zhou, Jing, primary, Mackay, Sean, primary, Rexer, Brent N., primary, Abramson, Vandana G., primary, Jansen, Valerie M., primary, Mallal, Simon, primary, Donaldson, Joshua, primary, Tolaney, Sara M., primary, Krop, Ian E., primary, Garrido-Castro, Ana C., primary, Marotti, Jonathan D., primary, Shee, Kevin, primary, Miller, Todd W., primary, Sanders, Melinda E., primary, Mayer, Ingrid A., primary, Salgado, Roberto, primary, and Balko, Justin M., primary

Published
2023
Full Text
View/download PDF

34. Supplementary fig 16 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

Author

Axelrod, Margaret L., primary, Nixon, Mellissa J., primary, Gonzalez-Ericsson, Paula I., primary, Bergman, Riley E., primary, Pilkinton, Mark A., primary, McDonnell, Wyatt J., primary, Sanchez, Violeta, primary, Opalenik, Susan R., primary, Loi, Sherene, primary, Zhou, Jing, primary, Mackay, Sean, primary, Rexer, Brent N., primary, Abramson, Vandana G., primary, Jansen, Valerie M., primary, Mallal, Simon, primary, Donaldson, Joshua, primary, Tolaney, Sara M., primary, Krop, Ian E., primary, Garrido-Castro, Ana C., primary, Marotti, Jonathan D., primary, Shee, Kevin, primary, Miller, Todd W., primary, Sanders, Melinda E., primary, Mayer, Ingrid A., primary, Salgado, Roberto, primary, and Balko, Justin M., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Dataset 2 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

Author

Axelrod, Margaret L., primary, Nixon, Mellissa J., primary, Gonzalez-Ericsson, Paula I., primary, Bergman, Riley E., primary, Pilkinton, Mark A., primary, McDonnell, Wyatt J., primary, Sanchez, Violeta, primary, Opalenik, Susan R., primary, Loi, Sherene, primary, Zhou, Jing, primary, Mackay, Sean, primary, Rexer, Brent N., primary, Abramson, Vandana G., primary, Jansen, Valerie M., primary, Mallal, Simon, primary, Donaldson, Joshua, primary, Tolaney, Sara M., primary, Krop, Ian E., primary, Garrido-Castro, Ana C., primary, Marotti, Jonathan D., primary, Shee, Kevin, primary, Miller, Todd W., primary, Sanders, Melinda E., primary, Mayer, Ingrid A., primary, Salgado, Roberto, primary, and Balko, Justin M., primary

Published
2023
Full Text
View/download PDF

36. Supplementary fig 6 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

Author

Axelrod, Margaret L., primary, Nixon, Mellissa J., primary, Gonzalez-Ericsson, Paula I., primary, Bergman, Riley E., primary, Pilkinton, Mark A., primary, McDonnell, Wyatt J., primary, Sanchez, Violeta, primary, Opalenik, Susan R., primary, Loi, Sherene, primary, Zhou, Jing, primary, Mackay, Sean, primary, Rexer, Brent N., primary, Abramson, Vandana G., primary, Jansen, Valerie M., primary, Mallal, Simon, primary, Donaldson, Joshua, primary, Tolaney, Sara M., primary, Krop, Ian E., primary, Garrido-Castro, Ana C., primary, Marotti, Jonathan D., primary, Shee, Kevin, primary, Miller, Todd W., primary, Sanders, Melinda E., primary, Mayer, Ingrid A., primary, Salgado, Roberto, primary, and Balko, Justin M., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Legends from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

Author

Axelrod, Margaret L., primary, Nixon, Mellissa J., primary, Gonzalez-Ericsson, Paula I., primary, Bergman, Riley E., primary, Pilkinton, Mark A., primary, McDonnell, Wyatt J., primary, Sanchez, Violeta, primary, Opalenik, Susan R., primary, Loi, Sherene, primary, Zhou, Jing, primary, Mackay, Sean, primary, Rexer, Brent N., primary, Abramson, Vandana G., primary, Jansen, Valerie M., primary, Mallal, Simon, primary, Donaldson, Joshua, primary, Tolaney, Sara M., primary, Krop, Ian E., primary, Garrido-Castro, Ana C., primary, Marotti, Jonathan D., primary, Shee, Kevin, primary, Miller, Todd W., primary, Sanders, Melinda E., primary, Mayer, Ingrid A., primary, Salgado, Roberto, primary, and Balko, Justin M., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

Author

Sharma, Priyanka, primary, Abramson, Vandana G., primary, O'Dea, Anne, primary, Nye, Lauren, primary, Mayer, Ingrid, primary, Pathak, Harsh B., primary, Hoffmann, Marc, primary, Stecklein, Shane R., primary, Elia, Manana, primary, Lewis, Sharon, primary, Scott, Jecinta, primary, De Jong, Jilliann A., primary, Wang, Yen Y., primary, Yoder, Rachel, primary, Schwensen, Kelsey, primary, Finke, Karissa, primary, Heldstab, Jaimie, primary, LaFaver, Stephanie, primary, Williamson, Stephen K., primary, Phadnis, Milind A., primary, Reed, Gregory A., primary, Kimler, Bruce F., primary, Khan, Qamar J., primary, and Godwin, Andrew K., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Data from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

Author

Axelrod, Margaret L., primary, Nixon, Mellissa J., primary, Gonzalez-Ericsson, Paula I., primary, Bergman, Riley E., primary, Pilkinton, Mark A., primary, McDonnell, Wyatt J., primary, Sanchez, Violeta, primary, Opalenik, Susan R., primary, Loi, Sherene, primary, Zhou, Jing, primary, Mackay, Sean, primary, Rexer, Brent N., primary, Abramson, Vandana G., primary, Jansen, Valerie M., primary, Mallal, Simon, primary, Donaldson, Joshua, primary, Tolaney, Sara M., primary, Krop, Ian E., primary, Garrido-Castro, Ana C., primary, Marotti, Jonathan D., primary, Shee, Kevin, primary, Miller, Todd W., primary, Sanders, Melinda E., primary, Mayer, Ingrid A., primary, Salgado, Roberto, primary, and Balko, Justin M., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 3 from Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

Author

Sharma, Priyanka, primary, Abramson, Vandana G., primary, O'Dea, Anne, primary, Nye, Lauren, primary, Mayer, Ingrid, primary, Pathak, Harsh B., primary, Hoffmann, Marc, primary, Stecklein, Shane R., primary, Elia, Manana, primary, Lewis, Sharon, primary, Scott, Jecinta, primary, De Jong, Jilliann A., primary, Wang, Yen Y., primary, Yoder, Rachel, primary, Schwensen, Kelsey, primary, Finke, Karissa, primary, Heldstab, Jaimie, primary, LaFaver, Stephanie, primary, Williamson, Stephen K., primary, Phadnis, Milind A., primary, Reed, Gregory A., primary, Kimler, Bruce F., primary, Khan, Qamar J., primary, and Godwin, Andrew K., primary

Published
2023
Full Text
View/download PDF

41. Supplementary fig 5 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

Author

Axelrod, Margaret L., primary, Nixon, Mellissa J., primary, Gonzalez-Ericsson, Paula I., primary, Bergman, Riley E., primary, Pilkinton, Mark A., primary, McDonnell, Wyatt J., primary, Sanchez, Violeta, primary, Opalenik, Susan R., primary, Loi, Sherene, primary, Zhou, Jing, primary, Mackay, Sean, primary, Rexer, Brent N., primary, Abramson, Vandana G., primary, Jansen, Valerie M., primary, Mallal, Simon, primary, Donaldson, Joshua, primary, Tolaney, Sara M., primary, Krop, Ian E., primary, Garrido-Castro, Ana C., primary, Marotti, Jonathan D., primary, Shee, Kevin, primary, Miller, Todd W., primary, Sanders, Melinda E., primary, Mayer, Ingrid A., primary, Salgado, Roberto, primary, and Balko, Justin M., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 2 from Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Author

Flaherty, Keith T., primary, LoRusso, Patricia M., primary, DeMichele, Angela, primary, Abramson, Vandana G., primary, Courtney, Rachel, primary, Randolph, Sophia S., primary, Shaik, M. Naveed, primary, Wilner, Keith D., primary, O'Dwyer, Peter J., primary, and Schwartz, Gary K., primary

Published
2023
Full Text
View/download PDF

43. Supplemental Figure 5 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67

Author

Jovanović, Bojana, primary, Mayer, Ingrid A., primary, Mayer, Erica L., primary, Abramson, Vandana G., primary, Bardia, Aditya, primary, Sanders, Melinda E., primary, Kuba, M. Gabriela, primary, Estrada, Monica V., primary, Beeler, J. Scott, primary, Shaver, Timothy M., primary, Johnson, Kimberly C., primary, Sanchez, Violeta, primary, Rosenbluth, Jennifer M., primary, Dillon, Patrick M., primary, Forero-Torres, Andres, primary, Chang, Jenny C., primary, Meszoely, Ingrid M., primary, Grau, Ana M., primary, Lehmann, Brian D., primary, Shyr, Yu, primary, Sheng, Quanhu, primary, Chen, Sheau-Chiann, primary, Arteaga, Carlos L., primary, and Pietenpol, Jennifer A., primary

Published
2023
Full Text
View/download PDF

44. Supplemental Figure 1 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67

Author

Jovanović, Bojana, primary, Mayer, Ingrid A., primary, Mayer, Erica L., primary, Abramson, Vandana G., primary, Bardia, Aditya, primary, Sanders, Melinda E., primary, Kuba, M. Gabriela, primary, Estrada, Monica V., primary, Beeler, J. Scott, primary, Shaver, Timothy M., primary, Johnson, Kimberly C., primary, Sanchez, Violeta, primary, Rosenbluth, Jennifer M., primary, Dillon, Patrick M., primary, Forero-Torres, Andres, primary, Chang, Jenny C., primary, Meszoely, Ingrid M., primary, Grau, Ana M., primary, Lehmann, Brian D., primary, Shyr, Yu, primary, Sheng, Quanhu, primary, Chen, Sheau-Chiann, primary, Arteaga, Carlos L., primary, and Pietenpol, Jennifer A., primary

Published
2023
Full Text
View/download PDF

45. Supplemental Figure 4 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67

Author

Jovanović, Bojana, primary, Mayer, Ingrid A., primary, Mayer, Erica L., primary, Abramson, Vandana G., primary, Bardia, Aditya, primary, Sanders, Melinda E., primary, Kuba, M. Gabriela, primary, Estrada, Monica V., primary, Beeler, J. Scott, primary, Shaver, Timothy M., primary, Johnson, Kimberly C., primary, Sanchez, Violeta, primary, Rosenbluth, Jennifer M., primary, Dillon, Patrick M., primary, Forero-Torres, Andres, primary, Chang, Jenny C., primary, Meszoely, Ingrid M., primary, Grau, Ana M., primary, Lehmann, Brian D., primary, Shyr, Yu, primary, Sheng, Quanhu, primary, Chen, Sheau-Chiann, primary, Arteaga, Carlos L., primary, and Pietenpol, Jennifer A., primary

Published
2023
Full Text
View/download PDF

46. Supplementary fig 2 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

Author

Axelrod, Margaret L., primary, Nixon, Mellissa J., primary, Gonzalez-Ericsson, Paula I., primary, Bergman, Riley E., primary, Pilkinton, Mark A., primary, McDonnell, Wyatt J., primary, Sanchez, Violeta, primary, Opalenik, Susan R., primary, Loi, Sherene, primary, Zhou, Jing, primary, Mackay, Sean, primary, Rexer, Brent N., primary, Abramson, Vandana G., primary, Jansen, Valerie M., primary, Mallal, Simon, primary, Donaldson, Joshua, primary, Tolaney, Sara M., primary, Krop, Ian E., primary, Garrido-Castro, Ana C., primary, Marotti, Jonathan D., primary, Shee, Kevin, primary, Miller, Todd W., primary, Sanders, Melinda E., primary, Mayer, Ingrid A., primary, Salgado, Roberto, primary, and Balko, Justin M., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 1 from Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Author

Flaherty, Keith T., primary, LoRusso, Patricia M., primary, DeMichele, Angela, primary, Abramson, Vandana G., primary, Courtney, Rachel, primary, Randolph, Sophia S., primary, Shaik, M. Naveed, primary, Wilner, Keith D., primary, O'Dwyer, Peter J., primary, and Schwartz, Gary K., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure Legends 1-2 from Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Author

Flaherty, Keith T., primary, LoRusso, Patricia M., primary, DeMichele, Angela, primary, Abramson, Vandana G., primary, Courtney, Rachel, primary, Randolph, Sophia S., primary, Shaik, M. Naveed, primary, Wilner, Keith D., primary, O'Dwyer, Peter J., primary, and Schwartz, Gary K., primary

Published
2023
Full Text
View/download PDF

49. Supplemental Figure 2 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67

Author

Jovanović, Bojana, primary, Mayer, Ingrid A., primary, Mayer, Erica L., primary, Abramson, Vandana G., primary, Bardia, Aditya, primary, Sanders, Melinda E., primary, Kuba, M. Gabriela, primary, Estrada, Monica V., primary, Beeler, J. Scott, primary, Shaver, Timothy M., primary, Johnson, Kimberly C., primary, Sanchez, Violeta, primary, Rosenbluth, Jennifer M., primary, Dillon, Patrick M., primary, Forero-Torres, Andres, primary, Chang, Jenny C., primary, Meszoely, Ingrid M., primary, Grau, Ana M., primary, Lehmann, Brian D., primary, Shyr, Yu, primary, Sheng, Quanhu, primary, Chen, Sheau-Chiann, primary, Arteaga, Carlos L., primary, and Pietenpol, Jennifer A., primary

Published
2023
Full Text
View/download PDF

50. Supplementary fig 4 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer

Author

Axelrod, Margaret L., primary, Nixon, Mellissa J., primary, Gonzalez-Ericsson, Paula I., primary, Bergman, Riley E., primary, Pilkinton, Mark A., primary, McDonnell, Wyatt J., primary, Sanchez, Violeta, primary, Opalenik, Susan R., primary, Loi, Sherene, primary, Zhou, Jing, primary, Mackay, Sean, primary, Rexer, Brent N., primary, Abramson, Vandana G., primary, Jansen, Valerie M., primary, Mallal, Simon, primary, Donaldson, Joshua, primary, Tolaney, Sara M., primary, Krop, Ian E., primary, Garrido-Castro, Ana C., primary, Marotti, Jonathan D., primary, Shee, Kevin, primary, Miller, Todd W., primary, Sanders, Melinda E., primary, Mayer, Ingrid A., primary, Salgado, Roberto, primary, and Balko, Justin M., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results